A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (NCT06384261)

🧪 Interventions in This Study

• Cusatuzumab (DRUG)
• Venetoclax (DRUG)
• Azacitidine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (38 Sites)

Showing the first 25 of 38 sites.

• Banner MD Anderson — Gilbert, Arizona
• City of Hope — Duarte, California
• University of California Los Angeles — Los Angeles, California
• University of Colorado Health - Anschutz Cancer Pavilion - Anschutz Medical Campus — Aurora, Colorado
• Yale School of Medicine — New Haven, Connecticut
• University of Miami - Sylvester Comprehensive Cancer Center - Miami — Miami, Florida
• AdventHealth Medical Group Blood & Marrow Transplant at Orlando — Orlando, Florida
• University of South Florida = Moffitt Cancer Center and Research Institute — Tampa, Florida
• The University of Iowa Hospitals & Clinics — Iowa City, Iowa
• University of Kentucky Chandler Medical Center — Lexington, Kentucky
• Norton Healthcare, Inc. — Louisville, Kentucky
• Hackensack University Medical Center — Hackensack, New Jersey
• Hofstra/Northwell Health — Lake Success, New York
• Cornell University — New York, New York
• University of Rochester Medical Center — Rochester, New York
• Wake Forest North Carolina — Winston-Salem, North Carolina
• Cleveland Clinic - Taussig Cancer Institute — Cleveland, Ohio
• Medical University of South Carolina — Charleston, South Carolina
• Fred Hutch Seattle Cancer Care Alliance — Seattle, Washington
• Medical College of Wisonsin — Milwaukee, Wisconsin
• Tom Baker Cancer Center-Alberta Health Services - University of Calgary — Calgary, Alberta
• Stollery Children's Hospital-Walter C Mackenzie Health Sciences Centre - University of Alberta — Edmonton, Alberta
• Vancouver General Hospital, Gordon and Leslie Diamond Health Care Centre — Vancouver, British Columbia
• University of Western Ontario — London, Ontario
• The Ottawa Hospital - General Campus — Ottawa, Ontario

📞 Contact the Study Coordinator

Phone: (877) 632-6789

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Leukemia, Myeloid, Acute

• Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia — Duarte, California
• A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy — Duarte, California
• A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies — Birmingham, Alabama
• A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms — Calgary, Alberta
• Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) — Houston, Texas

Explore by condition: All Leukemia, Myeloid, Acute clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.